News

Transgene Biotek Limited informed the BSE Limited that the company has not issued any Non-Convertible Securities, rendering Regulation 57(5) of the SEBI (LODR) Regulations, 2015 not applicable for the quarter ended September 30, 2026.

Transgene Biotek Limited informed the Bombay Stock Exchange that the Statement of Deviation or Variation under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is not applicable for the quarter ended September 30, 2026, due to the absence of a public issue, rights’ issue, or preferential issue during that period.

Transgene Biotek Limited informed the BSE Limited that Regulation 57 of SEBI’s (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company for the quarter ended September 30, 2026, as there are no non-convertible securities for which interest, dividend, or principal is payable.

Transgene Biotek Limited confirmed it does not meet the criteria to be classified as a “Large Corporate” under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and BSE Circular No. LIST/COM/05/2019 -20 dated April 11, 2019, in a filing with the BSE Limited on October 3, 2026.

Transgene Biotek confirmed compliance with Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that its Registrar and Share Transfer Agent, Bigshare Services Private Limited, a SEBI-registered Category-I agent with registration number INR000001385, maintains both physical and electronic share transfer facilities.